Arcus Biosciences Inc (RCUS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NYSE
Market Cap: $2.51B
Last updated: Nov 17, 2026 at 11:06 AM ET
Arcus Biosciences Inc (RCUS) Earnings: Report Dates and Results
Arcus Biosciences (RCUS) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Arcus Biosciences reported EPS of -$1.00, below the -$0.89 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
RCUS has an expected report date of Feb 23, 2027.
RCUS Earnings Call
The latest RCUS earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 35 quarters below that had an estimate, RCUS beat 22 and missed 13. Revenue for the quarter ended Sep 30, 2026 was $9.00M, down 65.4% from $26.00M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.00 | -$0.89 | -$1.00 - -$0.84 | -12.36% | Miss | N/A | 9 | 4 up, 2 down | Nov 4, 2026 | $9.00M |
| Jun 30, 2026 | -$0.72 | -$0.98 | -$1.04 - -$0.62 | +26.53% | Beat | N/A | 7 | 1 up, 0 down | Aug 5, 2026 | $41.00M |
| Mar 31, 2026 | -$1.02 | -$0.83 | -$1.01 - -$0.65 | -22.89% | Miss | N/A | 4 | 1 up, 0 down | May 5, 2026 | $17.00M |
| Dec 31, 2025 | -$0.89 | -$1.10 | -$1.11 - -$0.79 | +19.09% | Beat | N/A | 4 | 0 up, 1 down | Feb 25, 2026 | $33.00M |
| Sep 30, 2025 | -$1.27 | -$1.29 | -$1.32 - -$1.26 | +1.55% | Beat | N/A | 3 | 0 up, 2 down | Oct 28, 2025 | $26.00M |
| Jun 30, 2025 | $0.00 | -$1.17 | -$1.21 - -$1.10 | +100.00% | Beat | N/A | 3 | 0 up, 2 down | Aug 6, 2025 | $160.00M |
| Mar 31, 2025 | -$1.14 | -$1.01 | -$1.27 - -$0.80 | -12.87% | Miss | -700.0% | 4 | N/A | May 6, 2025 | $28.00M |
| Dec 31, 2024 | -$1.03 | -$1.20 | -$1.30 - -$0.99 | +14.39% | Beat | N/A | 6 | 2 up, 3 down | Feb 25, 2025 | $26.00M |
| Sep 30, 2024 | -$1.00 | -$1.07 | -$1.38 - -$0.85 | +6.54% | Beat | N/A | 11 | 1 up, 0 down | Nov 6, 2024 | $48.00M |
| Jun 30, 2024 | -$1.02 | -$1.39 | -$1.53 - -$0.80 | +26.62% | Beat | N/A | 9 | 0 up, 0 down | Aug 8, 2024 | $39.00M |
| Mar 31, 2024 | $0.19 | -$1.03 | -$1.21 - -$0.42 | +118.45% | Beat | N/A | 9 | 1 up, 1 down | May 8, 2024 | $145.00M |
| Dec 31, 2023 | -$1.08 | -$1.00 | -$1.21 - -$0.85 | -8.00% | Miss | N/A | 11 | 1 up, 1 down | Feb 21, 2024 | $31.00M |
| Sep 30, 2023 | -$0.94 | -$1.10 | -$1.23 - -$1.04 | +14.55% | Beat | N/A | 11 | 1 up, 0 down | Nov 7, 2023 | $32.00M |
| Jun 30, 2023 | -$1.04 | -$1.08 | -$1.27 - -$0.61 | +3.70% | Beat | N/A | 11 | 0 up, 0 down | Aug 7, 2023 | $29.00M |
| Mar 31, 2023 | -$1.09 | -$1.17 | -$1.59 - -$0.92 | +6.84% | Beat | N/A | 11 | 0 up, 0 down | May 9, 2023 | $25.00M |
| Dec 31, 2022 | -$0.93 | -$1.07 | -$1.22 - -$0.70 | +13.08% | Beat | -125.1% | 11 | 0 up, 0 down | Feb 28, 2023 | $34.00M |
| Sep 30, 2022 | -$0.90 | -$1.01 | -$1.13 - -$0.86 | +10.89% | Beat | N/A | 10 | 1 up, 0 down | Nov 2, 2022 | $33.00M |
| Jun 30, 2022 | -$0.93 | -$0.95 | -$1.00 - -$0.91 | +2.11% | Beat | N/A | 9 | 0 up, 0 down | Aug 3, 2022 | $27.00M |
| Mar 31, 2022 | -$0.96 | -$0.84 | -$0.94 - $4.19 | -14.29% | Miss | N/A | 9 | 0 up, 0 down | May 9, 2022 | $18.00M |
| Dec 31, 2021 | $3.71 | -$0.74 | -$1.17 - $1.71 | +601.35% | Beat | N/A | 8 | 0 up, 0 down | Feb 23, 2022 | $354.62M |
| Sep 30, 2021 | -$1.11 | -$1.03 | -$1.13 - -$0.91 | -7.77% | Miss | -3800.0% | 9 | 2 up, 0 down | Nov 8, 2021 | $9.46M |
| Jun 30, 2021 | -$1.09 | -$0.84 | -$1.18 - -$0.53 | -29.76% | Miss | N/A | 9 | N/A | Aug 5, 2021 | $9.46M |
| Mar 31, 2021 | -$1.08 | -$0.83 | -$1.08 - -$0.65 | -30.12% | Miss | N/A | 7 | N/A | May 5, 2021 | $9.46M |
| Dec 31, 2020 | -$0.82 | -$0.75 | -$1.01 - -$0.51 | -9.33% | Miss | N/A | 9 | N/A | Feb 24, 2021 | $9.97M |
| Sep 30, 2020 | $0.03 | -$0.76 | N/A | +103.95% | Beat | N/A | 8 | N/A | Nov 5, 2020 | $64.53M |
| Jun 30, 2020 | -$0.93 | -$0.58 | -$0.73 - -$0.52 | -60.34% | Miss | N/A | 8 | N/A | Aug 6, 2020 | $1.75M |
| Mar 31, 2020 | -$0.63 | -$0.56 | -$0.60 - -$0.53 | -12.50% | Miss | N/A | 8 | N/A | May 5, 2020 | $1.75M |
| Dec 31, 2019 | -$0.38 | -$0.51 | -$0.55 - -$0.47 | +25.49% | Beat | N/A | 6 | N/A | Mar 5, 2020 | $9.75M |
| Sep 30, 2019 | -$0.51 | -$0.52 | -$0.64 - -$0.39 | +1.92% | Beat | N/A | 6 | N/A | Nov 5, 2019 | $1.75M |
| Jun 30, 2019 | -$0.64 | -$0.41 | -$0.49 - -$0.30 | -56.10% | Miss | N/A | 5 | N/A | Aug 6, 2019 | $1.75M |
| Mar 31, 2019 | -$0.41 | -$0.35 | -$0.43 - -$0.30 | -17.14% | Miss | N/A | 4 | N/A | May 2, 2019 | $1.75M |
| Dec 31, 2018 | -$0.28 | -$0.45 | -$0.50 - -$0.41 | +37.78% | Beat | N/A | 4 | N/A | Mar 5, 2019 | $1.56M |
| Sep 30, 2018 | -$0.25 | -$0.35 | -$0.42 - -$0.35 | +28.57% | Beat | N/A | 4 | N/A | Nov 8, 2018 | $4.29M |
| Jun 30, 2018 | -$0.32 | -$0.40 | -$0.42 - -$0.38 | +20.00% | Beat | N/A | 3 | N/A | Aug 6, 2018 | $1.25M |
| Mar 31, 2018 | -$0.37 | -$0.43 | -$1.79 - -$0.39 | +13.95% | Beat | N/A | 3 | N/A | May 9, 2018 | $1.25M |
| Dec 31, 2017 | -$0.38 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 16, 2018 | $1.25M |
| Mar 31, 2017 | -$0.17 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2017 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$3.30, after -$2.86 the year before. It was -$0.55 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$3.30 | N/A |
| Dec 31, 2024 | -$2.86 | N/A |
| Dec 31, 2023 | -$4.15 | N/A |
| Dec 31, 2022 | -$3.72 | -965.1% |
| Dec 31, 2021 | $0.43 | N/A |
| Dec 31, 2020 | -$2.35 | N/A |
| Dec 31, 2019 | -$1.94 | N/A |
| Dec 31, 2018 | -$1.22 | N/A |
| Dec 31, 2017 | -$0.55 | N/A |
Earnings Calls
The 5 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 8,300 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 8,312 | 10 | |
| 2026Q1 | Mar 31, 2026 | 7,820 | 18 | |
| 2025Q4 | Dec 31, 2025 | 7,280 | 13 | |
| 2025Q1 | Mar 31, 2025 | 7,253 | 12 | |
| 2024Q3 | Sep 30, 2024 | 6,183 | 15 |
2026Q2 Earnings Call
Opening remarks
Pia Eaves Vice President, Investor Relations Good afternoon, and thank you for joining us on today's conference call to discuss Arcus' second quarter 2026 financial results and pipeline updates. I'd like to remind you that on this call, management will make forward-looking statements, including statements about our development strategies and our expectations regarding advantages and opportunities afforded by our investigational products, our clinical development milestones and timelines, our projected cash runway, and our financial outlook. All statements other than historical facts reflect the current beliefs and expectations of management and involve risks and uncertainties that may cause our actual results to differ from those expressed. Those risks and uncertainties are described in our most recent quarterly report on Form 10-Q that has been filed with the SEC. For today's call, please refer to our latest corporate presentation posted in the Investors section of our website. This afternoon, you'll hear from our CEO, Terry Rosen, CMO, Richard Markus, President Juan Jaen, and CFO, Robert Goeltz. With that, I'll turn the call over to Terry.
Terry Rosen CEO Thank you very much, Pia, and thanks so much, everyone, for joining us this afternoon. We continue to make substantial progress in advancing our portfolio of oncology and immunology programs. Execution throughout the first half of the year has been tremendous, and this tangible productivity will be a focus of today's discussion. Our highest priority, no surprise, continues to be the advancement of casdatifan, which we believe has clear potential to be a $5 to $10 billion drug. The remainder of our pipeline has also been advancing quite well, and we're beginning to share the details and breadth of our other programs. These create a steady and sustainable stream of additional opportunities, as well as strategic optionality. So starting with casdatifan, our next-generation HIF-2-alpha inhibitor. The advancement of cas has driven reflection and value for Arcus, and we expect further data this year to accelerate this reflection. Our first Phase III trial, PEAK-1, evaluating cas plus cabozantinib, the gold standard of care in second-line clear cell RCC, has tremendous investigator enthusiasm, and we remain on track to complete enrollment by the end of this year. Last year, we presented a wealth of data that demonstrated clearly casdatifan's efficacy advantages over belzutifan. Over the next 6 months, we will share new data that will provide clear line of sight to casdatifan's full market potential. Based upon casdatifan's superior profile, as well as our development strategy, we expect cas to become the backbone therapy for all patients in all lines of treatment in clear cell RCC, and we're maximizing that opportunity by rapidly expanding our development program. With the recent failure of Merck's LITESPARK-012 study, cas now has no competition in the frontline space.
Frequently Asked Questions About RCUS
When is Arcus Biosciences's next earnings date?
Arcus Biosciences's next earnings report is expected for Feb 23, 2027.
Did RCUS beat earnings estimates last quarter?
No. Arcus Biosciences reported EPS of -$1.00 for the quarter ended Sep 30, 2026, below the -$0.89 estimate by 12.36%.
What EPS do analysts expect from RCUS next quarter?
The consensus EPS estimate for Arcus Biosciences for the quarter ending Dec 31, 2026 is -$0.86 from 16 analysts, with estimates from -$0.98 to -$0.74.
How often does RCUS beat earnings estimates?
Arcus Biosciences beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +14.18%.
RCUS pages: Overview, Earnings, Forecast, Financials, Competitors